SOHO 2023 | Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri
• 6 Sep 2023
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, discusses the rationale behind the watch and wait approach in smoldering multiple myeloma (SMM), highlighting the lack of data supporting a standardized treatment for this disease. Dr Dispenzieri also talks on limitations of SMM studies, including the Phase III QuiRedex trial (NCT00480363) and the Phase III ECOG-E3A06 trial (NCT01169337). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
